Molecular therapies for malignant glioma
作者： Markus Hutterer , Eberhard Gunsilius , Guenther Stockhammer
DOI: 10.1007/S10354-006-0308-3
关键词: Immunology 、 Signal transduction 、 Monoclonal antibody 、 Antisense therapy 、 Imatinib mesylate 、 Medicine 、 Growth factor 、 Neovascularization 、 Cancer research 、 Glioma 、 Genetic enhancement
摘要: Due to the dismal prognosis of malignant glioma patients there is an urgent need for new innovative treatments based on a better understanding molecular mechanisms gliomagenesis. Several growth factor mediated pathways are critically involved in growth, invasiveness, and tumor neovascularization. Therefore, several concepts therapies directed against specific receptor-mediated signaling currently studied preclinical clinical settings. These include monoclonal antibodies, small inhibitors, antisense oligodeoxynucleotides.
springer.com
sci-hub.se 参考文章(152)
Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore, Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clinical Cancer Research. ,vol. 12, pp. 144- 151 ,(2006) , 10.1158/1078-0432.CCR-05-1571
Henrik Daub, Katja Specht, Axel Ullrich, Strategies to overcome resistance to targeted protein kinase inhibitors Nature Reviews Drug Discovery. ,vol. 3, pp. 1001- 1010 ,(2004) , 10.1038/NRD1579
David Schrama, Ralph A. Reisfeld, Jürgen C. Becker, Antibody targeted drugs as cancer therapeutics Nature Reviews Drug Discovery. ,vol. 5, pp. 147- 159 ,(2006) , 10.1038/NRD1957
Simon L. Goodman, Günter Hölzemann, Gábor A. G. Sulyok, Horst Kessler, Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins Journal of Medicinal Chemistry. ,vol. 45, pp. 1045- 1051 ,(2002) , 10.1021/JM0102598
Takao Kanzawa, Hideaki Ito, Yasuko Kondo, Seiji Kondo, Current and Future Gene Therapy for Malignant Gliomas. BioMed Research International. ,vol. 2003, pp. 25- 34 ,(2003) , 10.1155/S1110724303209013
J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, D. D. Bigner, A. H. Friedman, H. S. Friedman, Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clinical Cancer Research. ,vol. 13, pp. 1253- 1259 ,(2007) , 10.1158/1078-0432.CCR-06-2309
Hiroyuki Momota, Edward Nerio, Eric C. Holland, Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Research. ,vol. 65, pp. 7429- 7435 ,(2005) , 10.1158/0008-5472.CAN-05-1042
Whitney B Pope, A Lai, P Nghiemphu, P Mischel, TF Cloughesy, MRI in Patients With High-Grade Gliomas Treated With Bevacizumab and Chemotherapy Neurology. ,vol. 66, pp. 1258- 1260 ,(2006) , 10.1212/01.WNL.0000250628.10420.D8
D. Slamon, W Godolphin, L. Jones, J. Holt, S. Wong, D. Keith, W. Levin, S. Stuart, J Udove, A Ullrich, al. et, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. ,vol. 244, pp. 707- 712 ,(1989) , 10.1126/SCIENCE.2470152
Hope S. Rugo, Roy S. Herbst, Glenn Liu, John W. Park, Merrill S. Kies, Heidi M. Steinfeldt, Yazdi K. Pithavala, Steven D. Reich, James L. Freddo, George Wilding, Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results Journal of Clinical Oncology. ,vol. 23, pp. 5474- 5483 ,(2005) , 10.1200/JCO.2005.04.192